AmideBio, LLC, a privately held biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) Offices of Pediatric Therapeutics and Orphan Products Development granted a rare pediatric disease …
AMIDEBIO Granted Orphan Drug Designation by FDA for Novel Solution Stable Glucagon
AmideBio, LLC, a privately held biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) Office of Orphan Products Development granted an orphan drug designation to AmideBio’s glucagon …
AMIDEBIO Awarded $1.56M SBIR Phase II Grant to Further Development of its Novel Glucagons for the Treatment of Hyperinsulinism
AmideBio, LLC, a privately held biopharmaceutical company, announced today that it has received $1.56M in funding through a Phase II Small Business Innovation Research (SBIR) grant from the National Institute …
Contact
Contact us today.Thank you for visiting the AmideBio website. If you would like to receive additional information on our products, discuss potential collaboration or joint development opportunities, please contact us.Find …
About
About UsAmideBio discovers peptide therapeutics for metabolic disease. The company uses advanced in-silico techniques to intelligently design novel peptides, its proprietary technology (BioPure™ process) to efficiently generate them and testing …
Home
Novel Peptides Targeting Metabolic Disease Novel Peptides Targeting Metabolic Disease Novel Peptides Targeting Metabolic Disease Learn More AmideBio is leveraging its in-silico design and proprietary peptide synthesis capabilities to develop …
David Brunel Takes Over Chairmanship at AmideBio
BOULDER, CO, November 16, 2018 – AmideBio LLC, a privately held biopharmaceutical company, announced today that David Brunel, a board member of AmideBio, has assumed the role of Chairman of …
Diabetes Industry Veteran Pawel Fludzinski, Ph.D. assumed role of Company President of AmideBio
BOULDER, CO, September 4, 2018 – AmideBio LLC, a privately held biopharmaceutical company, announced today that Pawel Fludzinski, Ph.D. has assumed the role of Company President in addition to Chief …
Diabetes Industry Veteran Pawel Fludzinski, Ph.D. Named CEO of AmideBio
AmideBio LLC, a privately held biopharmaceutical company, announced today that Dr. Pawel Fludzinski has joined the Company as its new Chief Executive Officer. With his extensive background developing drugs targeting diabetes at …
Charles A. Stanley MD, joins AmideBio’s Scientific Advisory Board
BOULDER, CO, November 14, 2017 – AmideBio LLC, a privately held biopharmaceutical company, announced today that Charles A. Stanley MD will join its scientific advisory board. Dr. Stanley is a …